by
Gus Iversen, Editor in Chief | October 27, 2025
Ceregram, a noninvasive brain imaging tool developed by Vistim Labs, is now available for clinical use in neurology practices across the U.S., the Miami-based company announced this week.
The device is designed to offer clinicians a way to monitor the effectiveness of neurological treatments in-office, with imaging capabilities the company says approach the detail of PET scans but use electroencephalogram (EEG) technology. According to Vistim, this allows for routine, low-cost monitoring without the need for radiation or complex infrastructure.
Ceregram generates high-resolution, quantified brain images intended to help track changes in brain function and pathology, including amyloid buildup, one of the hallmarks of Alzheimer’s disease. It also incorporates standard EEG biomarkers. The tool is aimed at supporting treatment decisions in conditions like dementia, Parkinson’s disease and other neurodegenerative disorders by offering a clearer view into how patients are responding over time.
Ad Statistics
Times Displayed: 350
Times Visited: 1 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money.
“For the first time, neurologists can measure the effects of therapy over the course of treatment, and use this feedback loop to make timely, educated adjustments to the patient’s treatment plan,” said James Hamet, founder and CEO of Vistim Labs.
Vistim positions Ceregram not as a diagnostic tool, but as a treatment monitoring solution. Traditional imaging techniques like PET scans are often limited in availability and frequency due to cost and exposure concerns. Ceregram’s EEG-based approach could allow for more frequent imaging—potentially on a weekly basis, offering earlier insights into whether therapies are effective.
“Ceregram gives us the ability to see the brain change as we treat,” said Dr. Hanul Bhandari, chief medical officer at Vistim Labs.
The rollout follows a multiyear development effort supported by HITLAB, a digital health research organization. Stan Kachnowski, chair of HITLAB, said the partnership reflects “how evidence-based digital innovation can make world-class neuroimaging accessible.”
Vistim Labs plans to continue scaling access to Ceregram as part of its broader effort to integrate advanced neuro-monitoring tools into everyday neurological care.
